The top-performing drug models include targeted therapies against well-known cancer targets such as ERBBs, HDAC, BCL2, JAKs, PARP, ERK, CDKs, etc., and Lapatinib, Vincristine, and CAY10603 presented the best performing models with an average AUROC more than 0.9. The gene discussed is BCL2; the disease is cancer.